Charbal Bazo
Internal Medicine · Port Huron, MINPI 1689643496
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,740 of the $8,047 with a category attached, or 83.8%. It is spread thinly across 36 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boehringer Ingelheim$733
- GSK$692
- Novo Nordisk$624
- AstraZeneca$566
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$305
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$1,29216%
- Food & beverage$6,74084%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,808 |
| Boehringer Ingelheim | 36 | $733 |
| GSK | 54 | $692 |
| Novo Nordisk | 48 | $624 |
| AstraZeneca | 32 | $566 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $305 |
| Biohaven Pharmaceuticals, Inc. | 18 | $302 |
| Johnson & Johnson | 16 | $243 |
| Bayer | 11 | $237 |
| Merck | 17 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $215 |
| Orexo US, Inc. | 14 | $213 |
| Pfizer | 11 | $173 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $170 |
| Amgen | 11 | $170 |
| Otsuka America Pharmaceutical, Inc. | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 8 | $141 |
| Vanda Pharmaceuticals Inc. | 6 | $130 |
| Sanofi-aventis U.S. LLC | 3 | $113 |
| Eisai Inc. | 7 | $112 |
| Alkermes, Inc. | 6 | $107 |
| Supernus Pharmaceuticals, Inc. | 6 | $92 |
| Jazz Pharmaceuticals Inc. | 5 | $82 |
| Novartis | 4 | $61 |
| Almatica Pharma LLC | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Amarin Pharma, Inc. | 4 | $49 |
| Mylan Specialty L.p. | 3 | $49 |
| Indivior Inc. | 2 | $39 |
| Biogen | 2 | $30 |
| Lilly USA, LLC | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Fortovia Therapeutics, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $13 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,047 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,359 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,694 |
| Quetiapine Fumarate | 27 | $532 |
| Levothyroxine Sodium | 30 | $315 |
| Metformin Hcl | 23 | $278 |
| Metoprolol Succinate | 25 | $259 |
| Potassium Chloride | 22 | $238 |
| Ibuprofen | 30 | $226 |
| Tamsulosin Hcl | 20 | $215 |
| Amlodipine Besylate | 37 | $197 |
| Trazodone Hcl | 20 | $192 |
| Atorvastatin Calcium | 29 | $191 |
| Baclofen | 20 | $185 |
| Omeprazole | 27 | $167 |
| Pantoprazole Sodium | 15 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $692 | $9,35913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Port Huron
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.